Burning Rock Biotech Ltd
Research Burning Rock Biotech Ltd (BNR) on Bullrun: market cap USD 86.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBNR
- ExchangeNASDAQ
- CountryChina
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 86.10M
- Financial periodQ1 2026
- RevenueCNY 107.94M
- Net income-CNY 17.47M
- Free cash flow-CNY 29.30M
- Gross margin72.3%
Valuation Snapshot
latest market cap is USD 86.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 77.16M | -CNY 7.92M | -CNY 4.82M | 74.7% | -5.3 | CNY 68.41M | CNY 43.12M | CNY 76.54M |
| FY2024 | CNY 515.82M | -CNY 346.63M | -CNY 38.97M | 70.3% | -33.8 | CNY 519.85M | CNY 52.32M | CNY 580.83M |
| FY2023 | n/a | n/a | -CNY 265.17M | n/a | n/a | CNY 615.10M | CNY 12.32M | CNY 768.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 86.10M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 211.94M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 72.64M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 95.49M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 237.88M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.00B | n/a | n/a | n/a |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Burning Rock Biotech Ltd's market cap?
Burning Rock Biotech Ltd's market capitalization is USD 86.10M.
What does Burning Rock Biotech Ltd do?
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services.